Using two unique antibodies that selectively inhibit the function of CCL17 we have revealed that in order for this chemokine to function productively through CCR4 it requires concurrent interaction with two different binding sites on CCL17 [1] . CCR4 is known to interact with only one other ligand, CCL22, and the consequences of CCL17 vs CCL22 interaction with CCR4 are quite different. We have generated two antibodies, B202 and B225, which inhibit CCL17 function yet CCL22 inhibition can be mediated only by B202. Both antibodies perform comparably to block CCL17 function in vitro but differences become apparent in vivo. Methacholineinduced airway hyperresponsiveness (AHR) is effectively reversed by both antibodies but B225 was more effective at lowering IL-4 levels in the lung in the A. fumigatus model of chronic fungal asthma. Mice treated with B225 exhibited a more profound impact on inflammation in the lung accompanied by a decrease in mucus production compared to B202 treated mice as evident in histological analysis. One possible explanation for these disparities could be attributed to binding affinity for CCL17 as the difference in KD between the two antibodies is ~7-fold. However, this cannot fully account for the similarity in vitro. Further investigation of binding characteristics of B225 and B202 using competition binding studies revealed that B202 and B225 bind to non-competing epitopes on CCL17 and treatment with either one of these antibodies blocks CCL17 function through CCR4. This was somewhat surprising in that the size differential between CCL17 and the antibodies is > 15-fold so that the expectation was that any antibody binding to CCL17 would be capable of neutralizing function due to steric hindrance. This is the first report showing that CCL17 is required to engage two different binding sites to mediate CCR4 function.
Introduction
To understand the role of chemokine-mediated function in the immune response, attention has focused on receptor biology more so than that of the individual chemokines [2] [3] [4] [5] [6] [7] . One approach to study CCR4 biology has been to employ knock-out (KO) mice which, while informative, fail to adequately address the different functional consequences of CCL17 and CCL22 engagement with CCR4. [8, 9] These differences are most visible at the organismal level. For example one critical difference between CCL17 and
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CCL22 function is the effect on Treg homeostasis in that CCL17, but not CCL22 had been shown to modulate Treg function through its effect on dendritic cells, while CCL22 has been shown to play a more dominant role in Treg recruitment [10] [11] [12] [13] . In contrast, mouse models of invasive Aspergillosis have revealed that CCL17 suppresses the anti-fungal response whereas CCL22 is involved in mediating fungal clearance [14] . Though the CCR4 KO mice are useful for studies to understand receptor biology at the cellular level, they cannot be used to delineate the molecular events mediated by CCL17 and CCL22. The commercially available monoclonal anti-CCL17 antibody, MAB529, is a rat IgG2a antibody that inhibits CCL17 but not CCL22 function and although useful in vitro, may complicate interpretation of in vivo results due to Fcmediated effector function. In contrast, B225 and B202 are mouse: rat chimeric antibodies such that the Fv regions are derived from rat antibodies but the Fc regions have been converted to mouse IgG1which lacks effector function [15] . This eliminates any ambiguity surrounding contribution of the rat Fc in the interpretation of in vivo findings. These antibodies provide important tools that can be used to assess the outcome of selectively blocking CCL17 (B225) and delineate the mechanisms surrounding the differential impact on CCR4 function [10, 16] .
ThoughCCL17 and CCL22 interact with the same receptor they are only 37% identical [8] and neither chemokine has been demonstrated to act through any additional receptors. Since both chemokines are known to interact exclusively with CCR4, both compete for CCR4 binding and the most conserved regions are predicted to reside within the receptor binding site of each chemokine, one would expect to obtain a set of antibodies which crossreact with CCL17 and CCL22 [8, 17] . Despite this, only a single dual-reactive antibody, B202, was identified in our screen, representing <1% of the entire panel [15] . In addition to binding, B202 was also shown to block CCL22 function, although this effect was weak in that only partial inhibition was evident using conditions that were sufficient to completely inhibit CCL17 function. A second antibody, B225, was identified as CCL17-specific antibody that showed no cross reaction with CCL22. Relative performance of B202 and B225 in blocking CCL17-mediated calcium mobilization distinguishes B225 as the superior blocker of CCL17 function with calculated IC50 of 63.05 ng/mL compared to an IC50 of 225.4 ng/mL calculated for B202. Both antibodies performed comparably in the ability to inhibit CCL17-mediated chemotaxis although this assay is qualitative rather than quantitative. CCL22 binding by B202 is very weak (KD~2uM) as calculated using Biacore and was detectable by ELISA only in initial screens of hybridoma supernatants. No CCL22 binding could be detected for B225 regardless of the format.
That B225 and B202 specifically inhibit CCR4-mediated function was confirmed using a reporter cell line engineered to express CCR4 in the absence of other chemokine receptors. The readout for this assay was recruitment of ß-arrestin so that any effect of either chemokine can only be detected if mediated through CCR4 interaction. In contrast to the calcium mobilization assay the two antibodies performed almost indistinguishably in their ability to block CCL17-mediated ß-arrestin recruitment with estimated IC50s of ~100 nM.
While both B202 and B225 had comparable CCL17 neutralizing activity in vitro they behaved differently in vivo with B225 exhibiting a slightly superior outcome. Tested in the A. fumigatus model of chronic asthma, only B225 was able to ameliorate methacholine-induced AHR at the lower dose of antibody (200μg/mL) whereas both antibodies were able to do this at a 5-fold higher dose [1] . In addition B202 was less effective at modulating goblet cell metaplasia and mucus production in the lung; however, the difference is less obvious with respect to cytokine production. Mice treated with either antibody had increased IL-10 and decreased TNF-α in the lung. The only difference was in the ability to modulate IL-4 levels in that B225 was somewhat more effective at decreasing IL-4 although the differences were not statistically significant. Given that B202 inhibits CCL22 in addition to CCL17, one expectation would be that B202 would exhibit the more enhanced effect overall but this was not the case suggesting differences in the way the two antibodies interact with CCL17 were responsible for the differences in vivo.
To better understand how antibody interaction with CCL17 modulates function, binding studies were performed to compare the CCL17-specific antibodies having no detectable CCL22 binding, with the dual reactive B202. Competition binding analysis with MAB529 and B225 showed that these two antibodies bind distinct but overlapping epitopes on CCL17 while neither of these antibodies could compete with B202 for CCL17 binding. That all three of these antibodies inhibit CCL17 function strongly suggests that they are not all acting in the same manner. Because B202 cross-reacts with CCL22 and efficiently blocks CCL17 function it is likely that the epitope recognized by this antibody is highly conserved between the two chemokines. Further, it may indicate that CCL17 and CCL22 actually recognize the same region on CCR4 at least through this epitope. Then perhaps binding to a second site, which is blocked by B225, is the mechanism that confers specificity of each ligand.
The concept that CCL17 and CCL22 interact with CCR4 differently at the molecular level as well as the cellular and organismal level is not entirely new. Studies of chemotactic mechanisms have shown that CCL17 tends to foster cell rolling whereas CCL22 seems to promote cells to pause or slow movement as cells tend to stick rather than roll [18] . CCL22 more readily induces internalization of CCR4 than does CCL17 which may correlate with differences in binding affinities [8, 19, 20] . Previous reports of binding and functional studies using the chemokines themselves as competitors strongly supports the idea that CCL17 and CCL22 interact with CCR4 through a common binding site [8] . However, there are no previous reports addressing the possibility that CCR4 must engage two binding sites on CCL17 to mediate function. A recent paper shows there is differential binding of CCL17 and CCL22 to CCR4 which could help to explain the different outcomes associated with engagement by these ligands [2] . This is an interesting concept and complements our finding that CCL17 and CCL22 themselves differentially interact with CCR4 through an inherent mechanism.
